AZN Looks 9.6% Undervalued on GF Value™

On September 23, 2026, AstraZeneca PLC (NYSE: AZN) announced that the European Commission has approved its inhaler therapy, Trixeo Aerosphere, as a maintenance

KabuDo's automated read: this looks like a positive signal for healthcare. Potentially affected tickers include AZNN.MX (MX), AZN.L (GB), AZN (US), and 0A4J.L (GB).